Journal of Vaccines & Vaccination

Nanostatâ?¢ technology as an enabler of intranasal vaccination to induce mucosal immunity against viral and bacterial infection and carriage

10^th Euro Global Summit and Expo on Vaccines & Vaccination

June 16-18, 2016 Rome, Italy

Ali I Fattom

NanoBio Co., USA

Posters & Accepted Abstracts: J Vaccines Vaccin

Abstract:

Mucosal surfaces are the portal of entry for the majority of bacterial and viral pathogens. Nonetheless, almost all available vaccines are delivered intramuscularly (IM) for optimal induction of systemic immunity. Two major reasons why the field of mucosal immunity lacking behind. Lack of suitable delivery and adjuvants to facilitate mucosal immunity and difficulty in defining surrogate markers for protection as is the case with systemic immunization. NanoStatTM technology, a unique nanoemulsion (NE) based delivery/adjuvant was developed at the University of Michigan and shown to efficiently deliver vaccines intranasally (IN) and trigger a balanced Th2/Th1/and Th17 cell mediated immunity. This allow for simple intranasal self delivery of vaccines using droppers or spray and the immunological qualities and attributes make it well suited for respiratory and sexually transmitted diseases. Elicitation and homing of Th17, antibody producing B cells (IgG and IgA) and other T cells to mucosal tissues was confirmed using multiple vaccine targets including RSV, pertussis, pandemic flu HSV2, chlamydia and HIV. These findings suggest that an intranasal delivery/ adjuvant technology for induction of both systemic and mucosal immunity may be a favorable path for vaccines development to prevent infections as well as carriage and shedding of respiratory and sexually transmitted pathogens.

Biography :

Email: